ELITE TEST BANK:
MEDICAL-SURGICAL
NURSING CONCEPTS &
CLINICAL MASTERY
(2026/2027)
PART 0: THE NAVIGATOR
● PART I: THE PRIMER
○ The "Welcome to the Big Leagues" Hook
○ The "Panic Button" Cheat Sheet
● PART II: THE ELITE TEST BANK
○ Section 1: Foundational Syntax & Application (Q1–Q15)
○ Section 2: Professional Simulation (Q16–Q40)
○ Section 3: Grandmaster Synthesis (Q41–Q66)
PART I: THE PRIMER
Mastering medical-surgical nursing transforms the amateur into the apex clinical leader capable
of anticipating and averting multi-system physiological collapse. The 2026/2027 healthcare
environment demands zero hesitation, replacing rote academic memorization with absolute,
rapid-fire clinical intuition and precise execution aligned with the latest evidence-based
frameworks.
The "Panic Button" Cheat Sheet:
● Sepsis (SSC 2026): Shock (MAP < 65 mmHg or Lactate ≥ 4 mmol/L) triggers the STAT
1-Hour Bundle. Deploy 30 mL/kg balanced crystalloids and initiate peripheral
norepinephrine (16 mcg/mL concentration via 20G proximal to wrist) immediately.
● Burns (ABA 2026): Abandon the legacy 4 mL formula. Initiate the Rule of 10s (%TBSA ×
10 = mL/hr for adults 40–80 kg); titrate strictly to a 0.5–1.0 mL/kg/hr urine output to
prevent fluid creep.
● Heart Failure (AHA 2026): Guideline-Directed Medical Therapy (GDMT) mandates the
simultaneous, rapid initiation of four pillars (ARNI, Beta-Blocker, MRA, SGLT2i).
● Stroke (AHA 2026): Tenecteplase (TNK) 0.25 mg/kg IV single bolus over 5 seconds is
the definitive primary reperfusion standard.
● Diabetes (ADA 2026): GLP-1 receptor agonists are frontline for the
Cardio-Renal-Metabolic framework, prioritizing 5-7% weight loss and organ protection
independent of baseline A1C.
,PART II: THE ELITE TEST BANK
Section 1: Foundational Syntax & Application
Q1: A client with suspected pneumonia presents with a Mean Arterial Pressure (MAP) of 58
mmHg and a serum lactate of 4.8 mmol/L. According to the 2026 Surviving Sepsis Campaign
(SSC) guidelines, which hemodynamic intervention is the MOST APPROPRIATE INITIAL
action? A) Administer a 30 mL/kg IV crystalloid bolus and await central line placement for
vasopressor administration. B) Initiate broad-spectrum antimicrobials within 3 hours to allow
time for diagnostic imaging and culture verification. C) Deploy peripheral norepinephrine
immediately via a large-bore forearm intravenous line while concurrent fluids infuse. D)
Administer the qSOFA screening tool to formally confirm the diagnosis of septic shock before
intervening.
● The Answer: C (Deploy peripheral norepinephrine immediately via a large-bore forearm
intravenous line while concurrent fluids infuse.)
● Distractor Analysis:
○ A is incorrect: Waiting for central access delays life-saving perfusion and risks
permanent microvascular ischemia. 2026 standards dictate peripheral initiation.
○ B is incorrect: A MAP < 65 and lactate ≥ 4 trigger the STAT 1-hour bundle, not the
3-hour bundle. Time is tissue.
○ D is incorrect: The SSC explicitly advises against using qSOFA as a single
screening tool or delaying care for its completion.
The Mentor's Analysis: This is the Hard Deck of perfusion. A MAP below 65 mmHg combined
with an elevated lactate indicates profound tissue hypoxia and vasoplegia. Reversing
vasoplegia instantly is your apex priority. The 2026 standard mandates the immediate
administration of peripheral vasopressors (specifically dilute norepinephrine at 16 mcg/mL) to
force perfusion gradients while volume resuscitation is simultaneously ongoing. Professional
Intuition: Do not let the microcirculation die while waiting for a surgeon to place a central line.
Q2: A 70 kg adult sustains deep partial-thickness burns to 40% of their Total Body Surface Area
(TBSA). Utilizing the 2026 American Burn Association (ABA) Rule of 10s protocol, what is the
CORRECT initial hourly crystalloid resuscitation rate? A) 400 mL/hr B) 280 mL/hr C) 560 mL/hr
D) 800 mL/hr
● The Answer: A (400 mL/hr)
● Distractor Analysis:
○ B is incorrect: This represents a miscalculation using outdated pediatric or modified
formulas.
○ C is incorrect: This utilizes the legacy 4 mL/kg Parkland formula divided by 16
hours, which the 2026 ABA guidelines have abandoned for initial stabilization due
to fluid creep.
○ D is incorrect: This calculates the entire 8-hour volume but administers it as a
1-hour rate, leading to lethal pulmonary edema.
The Mentor's Analysis: The 2026 ABA standard utilizes the Rule of 10s to simplify cognitive
load during initial trauma stabilization.
Patient Weight Rule of 10s Calculation Example (40% TBSA)
40 kg - 80 kg % TBSA × 10 = mL/hr 40 × 10 = 400 mL/hr
> 80 kg (% TBSA × 10) + 100 mL per N/A for 70 kg
,Patient Weight Rule of 10s Calculation Example (40% TBSA)
10kg > 80kg
Professional Intuition: Formulas only start the engine; the hourly urine output (0.5-1.0
mL/kg/hr) steers the car.
Q3: An adult with a history of Type 2 Diabetes Mellitus and a BMI of 32 is being evaluated. Their
current A1C is 6.8%. Under the 2026 American Diabetes Association (ADA)
Cardio-Renal-Metabolic (CKM) framework, which pharmacological intervention is the
STRONGLY PREFERRED addition to their regimen? A) A sliding-scale rapid-acting insulin
protocol to strictly normalize postprandial glucose spikes. B) A Glucagon-like peptide-1 (GLP-1)
receptor agonist with demonstrated cardiovascular and metabolic benefits. C) A sulfonylurea to
maximize pancreatic beta-cell insulin secretion and rapidly lower A1C. D) Discontinuation of all
pharmacotherapy to attempt a strict 3-month trial of lifestyle modifications alone.
● The Answer: B (A Glucagon-like peptide-1 (GLP-1) receptor agonist with demonstrated
cardiovascular and metabolic benefits.)
● Distractor Analysis:
○ A is incorrect: Sliding-scale insulin is a reactive, outdated approach for stable
outpatient management and causes weight gain.
○ C is incorrect: Sulfonylureas increase the risk of hypoglycemia and weight gain,
contradicting the 2026 CKM goal of obesity management.
○ D is incorrect: While lifestyle is foundational, withholding proven cardio-protective
medications in an obese diabetic patient violates 2026 standards.
The Mentor's Analysis: The 2026 ADA guidelines definitively pivot away from glucocentric
tunnel vision (treating only the A1C) to a holistic cardiometabolic framework. GLP-1 receptor
agonists are now frontline for patients with a BMI > 30 and cardiovascular risk, regardless of
whether their A1C is already near target. Professional Intuition: We are no longer just treating
high sugar; we are actively preventing heart failure, kidney death, and metabolic syndrome
simultaneously.
Q4: A patient with Chronic Obstructive Pulmonary Disease (COPD) presents for a routine
follow-up. They have had one moderate exacerbation in the past year. Their blood eosinophil
count is 350 cells/µL. According to the 2026 GOLD guidelines, which inhaler regimen is the
MOST APPROPRIATE for this patient? A) A Short-Acting Beta Agonist (SABA) used strictly on
a PRN basis. B) Dual therapy with a LABA and a LAMA, completely avoiding steroids to prevent
pneumonia. C) Triple therapy including a LABA, LAMA, and an Inhaled Corticosteroid (ICS). D)
A daily oral systemic corticosteroid to suppress systemic type-2 inflammation.
● The Answer: C (Triple therapy including a LABA, LAMA, and an Inhaled Corticosteroid
(ICS).)
● Distractor Analysis:
○ A is incorrect: SABA-only therapy is obsolete for maintenance of actively
exacerbating COPD.
○ B is incorrect: While LABA/LAMA is standard for Group B, the presence of high
eosinophils demands the addition of an ICS.
○ D is incorrect: Daily systemic oral steroids cause massive metabolic side effects
(osteoporosis, hyperglycemia) and are not used for baseline maintenance.
The Mentor's Analysis: The 2026 GOLD report lowered the threshold for escalation. Even one
moderate exacerbation indicates high disease activity. Crucially, a blood eosinophil count ≥ 300
cells/µL is the definitive biomarker indicating that the patient will respond to an Inhaled
Corticosteroid (ICS). Professional Intuition: Eosinophils equal steroids. When type-2
, inflammation is driving the airway destruction, you must deploy an ICS to halt the cascade.
Q5: A client arrives at the emergency department with acute ischemic stroke symptoms. Onset
was witnessed 2 hours ago. CT scan rules out hemorrhage. Which pharmacological intervention
represents the 2026 APEX STANDARD for primary reperfusion? A) Alteplase (tPA) 0.9 mg/kg
administered via a 60-minute continuous infusion. B) Dual Antiplatelet Therapy (DAPT) loaded
immediately with Clopidogrel and Aspirin. C) Tenecteplase (TNK) 0.25 mg/kg administered as a
single 5-second IV bolus. D) Therapeutic dose unfractionated heparin titrated to an aPTT of
60-80 seconds.
● The Answer: C (Tenecteplase (TNK) 0.25 mg/kg administered as a single 5-second IV
bolus.)
● Distractor Analysis:
○ A is incorrect: While tPA is historically accurate, TNK has superseded it in 2026 elite
protocols due to superior reperfusion profiles and administration speed.
○ B is incorrect: DAPT is for secondary prevention or non-thrombolytic candidates,
not acute primary chemical reperfusion.
○ D is incorrect: Heparin is contraindicated in the acute phase of an ischemic stroke
due to the high risk of hemorrhagic transformation.
The Mentor's Analysis: Time is Brain. Tenecteplase (TNK) is a genetically engineered variant
of tPA that boasts higher fibrin specificity and a longer half-life. This allows for a one-and-done
5-second push, eliminating the need for infusion pumps during transport and enabling the 2026
Direct-to-Thrombectomy model. Professional Intuition: Always select the intervention that
minimizes door-to-needle and door-in-door-out (DIDO) times.
Q6: A patient with heart failure with reduced ejection fraction (HFrEF) is preparing for hospital
discharge. To adhere to 2026 AHA Guideline-Directed Medical Therapy (GDMT), the nurse
ensures the patient is prescribed which MANDATORY combination of medications? A) An ACE
inhibitor, a loop diuretic, and a statin. B) An ARNI, a Beta-Blocker, a Mineralocorticoid Receptor
Antagonist (MRA), and an SGLT2 inhibitor. C) Digoxin, a calcium channel blocker, and a
thiazide diuretic. D) An Angiotensin Receptor Blocker (ARB) and a daily aspirin.
● The Answer: B (An ARNI, a Beta-Blocker, a Mineralocorticoid Receptor Antagonist
(MRA), and an SGLT2 inhibitor.)
● Distractor Analysis:
○ A is incorrect: This is legacy therapy. Loop diuretics manage fluid but do not alter
disease mortality, and ACE inhibitors have been largely replaced by ARNIs.
○ C is incorrect: Digoxin is a salvage inotrope, not a foundational disease-modifying
pillar.
○ D is incorrect: ARBs are acceptable if ARNIs are untolerated, but combining it only
with aspirin ignores three other necessary mortality-reducing pathways.
The Mentor's Analysis: The 2026 AHA guidelines abandoned the slow, multi-year stepwise
titration of heart failure drugs. GDMT now requires the rapid, simultaneous initiation of the "Four
Pillars" to instantly block neurohormonal remodeling, induce diuresis, and protect renal function.
Professional Intuition: Do not discharge a HFrEF patient without the four pillars unless
explicitly contraindicated; doing so is clinical negligence.
Q7: A client is admitted with an acute kidney injury (AKI). Laboratory results show a serum
potassium of 6.8 mEq/L and the ECG displays tall, peaked T-waves. Which intervention is the
ABSOLUTE FIRST priority? A) Administer sodium polystyrene sulfonate (Kayexalate) orally to
excrete potassium via the GI tract. B) Administer 10 units of regular insulin IV push alongside 50
mL of 50% Dextrose. C) Administer IV calcium gluconate to stabilize the myocardial resting
membrane potential. D) Prepare the patient for emergent continuous venovenous hemofiltration
MEDICAL-SURGICAL
NURSING CONCEPTS &
CLINICAL MASTERY
(2026/2027)
PART 0: THE NAVIGATOR
● PART I: THE PRIMER
○ The "Welcome to the Big Leagues" Hook
○ The "Panic Button" Cheat Sheet
● PART II: THE ELITE TEST BANK
○ Section 1: Foundational Syntax & Application (Q1–Q15)
○ Section 2: Professional Simulation (Q16–Q40)
○ Section 3: Grandmaster Synthesis (Q41–Q66)
PART I: THE PRIMER
Mastering medical-surgical nursing transforms the amateur into the apex clinical leader capable
of anticipating and averting multi-system physiological collapse. The 2026/2027 healthcare
environment demands zero hesitation, replacing rote academic memorization with absolute,
rapid-fire clinical intuition and precise execution aligned with the latest evidence-based
frameworks.
The "Panic Button" Cheat Sheet:
● Sepsis (SSC 2026): Shock (MAP < 65 mmHg or Lactate ≥ 4 mmol/L) triggers the STAT
1-Hour Bundle. Deploy 30 mL/kg balanced crystalloids and initiate peripheral
norepinephrine (16 mcg/mL concentration via 20G proximal to wrist) immediately.
● Burns (ABA 2026): Abandon the legacy 4 mL formula. Initiate the Rule of 10s (%TBSA ×
10 = mL/hr for adults 40–80 kg); titrate strictly to a 0.5–1.0 mL/kg/hr urine output to
prevent fluid creep.
● Heart Failure (AHA 2026): Guideline-Directed Medical Therapy (GDMT) mandates the
simultaneous, rapid initiation of four pillars (ARNI, Beta-Blocker, MRA, SGLT2i).
● Stroke (AHA 2026): Tenecteplase (TNK) 0.25 mg/kg IV single bolus over 5 seconds is
the definitive primary reperfusion standard.
● Diabetes (ADA 2026): GLP-1 receptor agonists are frontline for the
Cardio-Renal-Metabolic framework, prioritizing 5-7% weight loss and organ protection
independent of baseline A1C.
,PART II: THE ELITE TEST BANK
Section 1: Foundational Syntax & Application
Q1: A client with suspected pneumonia presents with a Mean Arterial Pressure (MAP) of 58
mmHg and a serum lactate of 4.8 mmol/L. According to the 2026 Surviving Sepsis Campaign
(SSC) guidelines, which hemodynamic intervention is the MOST APPROPRIATE INITIAL
action? A) Administer a 30 mL/kg IV crystalloid bolus and await central line placement for
vasopressor administration. B) Initiate broad-spectrum antimicrobials within 3 hours to allow
time for diagnostic imaging and culture verification. C) Deploy peripheral norepinephrine
immediately via a large-bore forearm intravenous line while concurrent fluids infuse. D)
Administer the qSOFA screening tool to formally confirm the diagnosis of septic shock before
intervening.
● The Answer: C (Deploy peripheral norepinephrine immediately via a large-bore forearm
intravenous line while concurrent fluids infuse.)
● Distractor Analysis:
○ A is incorrect: Waiting for central access delays life-saving perfusion and risks
permanent microvascular ischemia. 2026 standards dictate peripheral initiation.
○ B is incorrect: A MAP < 65 and lactate ≥ 4 trigger the STAT 1-hour bundle, not the
3-hour bundle. Time is tissue.
○ D is incorrect: The SSC explicitly advises against using qSOFA as a single
screening tool or delaying care for its completion.
The Mentor's Analysis: This is the Hard Deck of perfusion. A MAP below 65 mmHg combined
with an elevated lactate indicates profound tissue hypoxia and vasoplegia. Reversing
vasoplegia instantly is your apex priority. The 2026 standard mandates the immediate
administration of peripheral vasopressors (specifically dilute norepinephrine at 16 mcg/mL) to
force perfusion gradients while volume resuscitation is simultaneously ongoing. Professional
Intuition: Do not let the microcirculation die while waiting for a surgeon to place a central line.
Q2: A 70 kg adult sustains deep partial-thickness burns to 40% of their Total Body Surface Area
(TBSA). Utilizing the 2026 American Burn Association (ABA) Rule of 10s protocol, what is the
CORRECT initial hourly crystalloid resuscitation rate? A) 400 mL/hr B) 280 mL/hr C) 560 mL/hr
D) 800 mL/hr
● The Answer: A (400 mL/hr)
● Distractor Analysis:
○ B is incorrect: This represents a miscalculation using outdated pediatric or modified
formulas.
○ C is incorrect: This utilizes the legacy 4 mL/kg Parkland formula divided by 16
hours, which the 2026 ABA guidelines have abandoned for initial stabilization due
to fluid creep.
○ D is incorrect: This calculates the entire 8-hour volume but administers it as a
1-hour rate, leading to lethal pulmonary edema.
The Mentor's Analysis: The 2026 ABA standard utilizes the Rule of 10s to simplify cognitive
load during initial trauma stabilization.
Patient Weight Rule of 10s Calculation Example (40% TBSA)
40 kg - 80 kg % TBSA × 10 = mL/hr 40 × 10 = 400 mL/hr
> 80 kg (% TBSA × 10) + 100 mL per N/A for 70 kg
,Patient Weight Rule of 10s Calculation Example (40% TBSA)
10kg > 80kg
Professional Intuition: Formulas only start the engine; the hourly urine output (0.5-1.0
mL/kg/hr) steers the car.
Q3: An adult with a history of Type 2 Diabetes Mellitus and a BMI of 32 is being evaluated. Their
current A1C is 6.8%. Under the 2026 American Diabetes Association (ADA)
Cardio-Renal-Metabolic (CKM) framework, which pharmacological intervention is the
STRONGLY PREFERRED addition to their regimen? A) A sliding-scale rapid-acting insulin
protocol to strictly normalize postprandial glucose spikes. B) A Glucagon-like peptide-1 (GLP-1)
receptor agonist with demonstrated cardiovascular and metabolic benefits. C) A sulfonylurea to
maximize pancreatic beta-cell insulin secretion and rapidly lower A1C. D) Discontinuation of all
pharmacotherapy to attempt a strict 3-month trial of lifestyle modifications alone.
● The Answer: B (A Glucagon-like peptide-1 (GLP-1) receptor agonist with demonstrated
cardiovascular and metabolic benefits.)
● Distractor Analysis:
○ A is incorrect: Sliding-scale insulin is a reactive, outdated approach for stable
outpatient management and causes weight gain.
○ C is incorrect: Sulfonylureas increase the risk of hypoglycemia and weight gain,
contradicting the 2026 CKM goal of obesity management.
○ D is incorrect: While lifestyle is foundational, withholding proven cardio-protective
medications in an obese diabetic patient violates 2026 standards.
The Mentor's Analysis: The 2026 ADA guidelines definitively pivot away from glucocentric
tunnel vision (treating only the A1C) to a holistic cardiometabolic framework. GLP-1 receptor
agonists are now frontline for patients with a BMI > 30 and cardiovascular risk, regardless of
whether their A1C is already near target. Professional Intuition: We are no longer just treating
high sugar; we are actively preventing heart failure, kidney death, and metabolic syndrome
simultaneously.
Q4: A patient with Chronic Obstructive Pulmonary Disease (COPD) presents for a routine
follow-up. They have had one moderate exacerbation in the past year. Their blood eosinophil
count is 350 cells/µL. According to the 2026 GOLD guidelines, which inhaler regimen is the
MOST APPROPRIATE for this patient? A) A Short-Acting Beta Agonist (SABA) used strictly on
a PRN basis. B) Dual therapy with a LABA and a LAMA, completely avoiding steroids to prevent
pneumonia. C) Triple therapy including a LABA, LAMA, and an Inhaled Corticosteroid (ICS). D)
A daily oral systemic corticosteroid to suppress systemic type-2 inflammation.
● The Answer: C (Triple therapy including a LABA, LAMA, and an Inhaled Corticosteroid
(ICS).)
● Distractor Analysis:
○ A is incorrect: SABA-only therapy is obsolete for maintenance of actively
exacerbating COPD.
○ B is incorrect: While LABA/LAMA is standard for Group B, the presence of high
eosinophils demands the addition of an ICS.
○ D is incorrect: Daily systemic oral steroids cause massive metabolic side effects
(osteoporosis, hyperglycemia) and are not used for baseline maintenance.
The Mentor's Analysis: The 2026 GOLD report lowered the threshold for escalation. Even one
moderate exacerbation indicates high disease activity. Crucially, a blood eosinophil count ≥ 300
cells/µL is the definitive biomarker indicating that the patient will respond to an Inhaled
Corticosteroid (ICS). Professional Intuition: Eosinophils equal steroids. When type-2
, inflammation is driving the airway destruction, you must deploy an ICS to halt the cascade.
Q5: A client arrives at the emergency department with acute ischemic stroke symptoms. Onset
was witnessed 2 hours ago. CT scan rules out hemorrhage. Which pharmacological intervention
represents the 2026 APEX STANDARD for primary reperfusion? A) Alteplase (tPA) 0.9 mg/kg
administered via a 60-minute continuous infusion. B) Dual Antiplatelet Therapy (DAPT) loaded
immediately with Clopidogrel and Aspirin. C) Tenecteplase (TNK) 0.25 mg/kg administered as a
single 5-second IV bolus. D) Therapeutic dose unfractionated heparin titrated to an aPTT of
60-80 seconds.
● The Answer: C (Tenecteplase (TNK) 0.25 mg/kg administered as a single 5-second IV
bolus.)
● Distractor Analysis:
○ A is incorrect: While tPA is historically accurate, TNK has superseded it in 2026 elite
protocols due to superior reperfusion profiles and administration speed.
○ B is incorrect: DAPT is for secondary prevention or non-thrombolytic candidates,
not acute primary chemical reperfusion.
○ D is incorrect: Heparin is contraindicated in the acute phase of an ischemic stroke
due to the high risk of hemorrhagic transformation.
The Mentor's Analysis: Time is Brain. Tenecteplase (TNK) is a genetically engineered variant
of tPA that boasts higher fibrin specificity and a longer half-life. This allows for a one-and-done
5-second push, eliminating the need for infusion pumps during transport and enabling the 2026
Direct-to-Thrombectomy model. Professional Intuition: Always select the intervention that
minimizes door-to-needle and door-in-door-out (DIDO) times.
Q6: A patient with heart failure with reduced ejection fraction (HFrEF) is preparing for hospital
discharge. To adhere to 2026 AHA Guideline-Directed Medical Therapy (GDMT), the nurse
ensures the patient is prescribed which MANDATORY combination of medications? A) An ACE
inhibitor, a loop diuretic, and a statin. B) An ARNI, a Beta-Blocker, a Mineralocorticoid Receptor
Antagonist (MRA), and an SGLT2 inhibitor. C) Digoxin, a calcium channel blocker, and a
thiazide diuretic. D) An Angiotensin Receptor Blocker (ARB) and a daily aspirin.
● The Answer: B (An ARNI, a Beta-Blocker, a Mineralocorticoid Receptor Antagonist
(MRA), and an SGLT2 inhibitor.)
● Distractor Analysis:
○ A is incorrect: This is legacy therapy. Loop diuretics manage fluid but do not alter
disease mortality, and ACE inhibitors have been largely replaced by ARNIs.
○ C is incorrect: Digoxin is a salvage inotrope, not a foundational disease-modifying
pillar.
○ D is incorrect: ARBs are acceptable if ARNIs are untolerated, but combining it only
with aspirin ignores three other necessary mortality-reducing pathways.
The Mentor's Analysis: The 2026 AHA guidelines abandoned the slow, multi-year stepwise
titration of heart failure drugs. GDMT now requires the rapid, simultaneous initiation of the "Four
Pillars" to instantly block neurohormonal remodeling, induce diuresis, and protect renal function.
Professional Intuition: Do not discharge a HFrEF patient without the four pillars unless
explicitly contraindicated; doing so is clinical negligence.
Q7: A client is admitted with an acute kidney injury (AKI). Laboratory results show a serum
potassium of 6.8 mEq/L and the ECG displays tall, peaked T-waves. Which intervention is the
ABSOLUTE FIRST priority? A) Administer sodium polystyrene sulfonate (Kayexalate) orally to
excrete potassium via the GI tract. B) Administer 10 units of regular insulin IV push alongside 50
mL of 50% Dextrose. C) Administer IV calcium gluconate to stabilize the myocardial resting
membrane potential. D) Prepare the patient for emergent continuous venovenous hemofiltration
